Amiodarone corrects dangerous, chaotic heart rhythms by acting on multiple electrical pathways in the heart simultaneously. It primarily prolongs the time it takes for heart muscle cells to recharge between beats, effectively slamming the brakes on rapid, disorganised electrical circuits. It also blocks the effects of adrenaline on the heart and slows electrical conduction through the heart's natural pacemaker nodes. Because it acts on so many different targets at once, it is highly effective at restoring and maintaining a normal heartbeat even when other medications have failed.
Synthesized by chemists at Labaz Laboratories in Belgium, the drug was developed through structural modification of khellin—a natural compound extracted from the plant Ammi visnaga (Bishop's weed) which was known to possess coronary vasodilator properties. Iodine was added to the benzofuran ring to increase its lipid solubility.
Amiodarone was synthesized in 1961 by Tondeur and Binon as a coronary vasodilator and introduced in Europe in 1962 to treat angina pectoris. It was briefly withdrawn in 1967 due to extracardiac side effects. In 1970, Argentine physician Mauricio Rosenbaum discovered its remarkable efficacy against refractory ventricular and supraventricular arrhythmias, sparking a global resurgence of interest. Throughout the late 1970s and early 1980s, physicians in the United States began importing the drug from Europe for patients with life-threatening arrhythmias who had exhausted all other options. Confronted by immense clinical pressure and overwhelming observational evidence of efficacy in desperate cases, the United States Food and Drug Administration (FDA) officially approved oral amiodarone in 1985—bypassing the standard requirement for randomized, placebo-controlled clinical trials, a rare regulatory concession.
Originally developed and approved in Europe as a coronary vasodilator for the symptomatic treatment of angina pectoris.